Based on the evidence presented in this report, this modified LFIA had a high potential to become an accurate, simple, and rapid diagnostic test for accurate prediction of the malignant propensity of clinical prostate cancer at the premalignant stage, which is different from the PSA test. This evidence concerns the gene KLK3 and prostate cancer.